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Abstract
Cryptococcus neoformans is an emerging pathogen that kills hundreds of thousands every
year, especially in underdeveloped areas with little access to modern medical care. New
treatments for the disease are needed to shorten treatment and decrease the side effects
and costs associated with the drugs currently in use. Many C. neoformans genes have
been identified that are necessary for full virulence in the host. Cir1, a regulatory protein
associated with iron regulation, and Zip1, a surface zinc transporter, are both necessary
for full virulence in the host. Anti-fungals targeted at these proteins or the proteins
produced by other genes discussed in this paper could help treat this AIDS-defining
illness more effectively.
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Non-Capsular Virulence Factors of Cryptococcus neoformans
Introduction
Cryptococcus neoformans is a fungal pathogen that mainly infects
immunocompromised individuals and is an AIDS defining illness. The death rates for
patients who complete the full course of treatment are extremely low, however, if the full
course of treatment cannot be carried out the prognosis is poor. A very high percentage of
C. neoformans infections in immunocompromised individuals in sub-Saharan Africa
result in death, even when treatment with fluconazole is performed (Mwaba et al., 2001;
Oumar, Dao, Ba, Poudiougou, & Diallo, 2008). This disease is the fourth most deadly in
the sub-Saharan region, where it kills more than 500,000 people per year (Park et al.,
2009). Alternative methods for the reduction of both the virulence of the pathogen and
the length of the course of treatment are needed to improve the survival rate of those
without easy access to medical care.
Cryptococcosis has spread concurrently with HIV in Africa and India, and has
become a much higher priority illness to treat in recent years. A C. neoformans infection
requires a much longer treatment course than that required by other prevalent African
diseases, such as malaria or other parasitic infections. Current treatment indicates an 8week course of amphotericin B and flucytosine, followed by daily fluconazole for a year.
This treatment plan is very effective and has a high success rate. However, for those
without easy access to medical services, a yearlong course of fluconazole may well be
out of reach, contributing to the high rate of mortalities to the disease observed in subSaharan Africa. The need for regularly administered antifungals as well as the toxicity of
those medicines make completing a full course of treatment very difficult. Amphotericin
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B in particular is extremely toxic and can cause blurred vision and weakness. Flucytosine
also has relatively severe side effects, ranging from diarrhea and jaundice to headaches
and hallucinations. An ongoing shortage of flucytosine also contributes to the difficulties
associated with obtaining appropriate treatment in developing countries.
The side effects from these drugs are often severe, and further increase the
economic barriers preventing patients from being able to complete a full course of
treatment. The Amphotericin B necessary at the start of treatment alone costs more than
the average annual income of a resident of sub-saharan Africa. When combined with the
necessary length of treatment and the need for maintenance anti-fungals for extended
periods following initial treatment, it is no surprise that mortality rates are elevated in this
region. New treatment options are badly needed; especially drugs that can treat
Cryptococcus infection more rapidly or completely eliminate it from the patient,
preventing the need for maintenance fluconazole.
C. neoformans is an encapsulated yeast from the phylum Basidiomycota, which
also includes the mushrooms, rusts, and smuts. Cryptococcus is also the only known
genera of fungi to have a polysaccharide capsule. It tends to proliferate in the
cerebrospinal fluid, among other locations, metabolizing the glucose in the CSF as its
main carbon source. This proliferation can lead to meningitis (swelling of the meninges)
and encephalitis (inflammation of the brain) due to immune response to the pathogen.
Both conditions are serious and potentially life threatening. The organism can go dormant
for extended periods of time, in some cases for ten years or more, only reappearing when
the host becomes immunocompromised (Garcia-Hermoso, Janbon, & Dromer, 1999). C.
neoformans also produces melanin, a darkening pigment required for virulence, in much
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the same manner that the human body does. The production of melanin in the capsule
helps protect the yeast from attacks by host immune cells. Once in the body, the yeast
must also be able to grow at 37oC in order to thrive in the host. Many of the mutant forms
of C. neoformans exhibit temperature sensitivity at 37°C, attenuating their virulence or
rendering them completely harmless.
There are several strain variants with different capsule structures with at least one
substituting xylose for the mannose backbone in the matrix. Two main serotypes of
Cryptococcus have been characterized in the literature, as well as an interstrain hybrid
variant (Enache-Angoulvant et al., 2007; Hagen et al., 2015). C. neoformans var.
neoformans is comprised of serotype D, whereas C. neoformans var. grubii is also known
as serotype A, while C. gatii contain both serotypes B and C. C. gattii was formerly
considered a subspecies of C. neoformans (Hagen et al., 2015). The H99 clinical strain of
C. neoformans is serotype A, while the JEC21 laboratory strain is a serotype D
strain(Loftus et al., 2005). A serotype AD strain has also been identified and is the most
widespread of the hybrid serotypes. More serotypes are presumed to exist, but have not
yet been characterized (Banerjee, Datta, & Casadevall, 2004).
Pathology
Initial infection by C. neoformans is alveolar, as the pathogen in its virulent form
is airborne. Basidiospores, or sexually-produced reproductive spores, are believed to be
the initial source of the infection; the vegetative cells are too large to enter the lung
parenchyma. After entrance to the lung, the now-active cells are absorbed by the alveolar
macrophages present in the lung tissue. However, phagocytosis by immune cells does not
kill the yeast; it is able to survive inside of the macrophage due to its unique capsule,
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where it is shielded from interaction with the immune system. Inside the macrophage, C.
neoformans can grow and reproduce, creating a phagosome filled with new cells inside of
the macrophage. After reproducing and combining with other phagosomes, C.
neoformans is capable of triggering its own release from the macrophage (Alvarez &
Casadevall, 2006; H. Ma, Croudace, Lammas, & May, 2006). The phagosome is
extruded by a process known as vomocytosis, in which the intracellular actin used to hold
the phagosome in place is degraded (Alvarez & Casadevall, 2006; Nicola, Robertson,
Albuquerque, Derengowski Lda, & Casadevall, 2011). This process is similar to that
observed in Mycobacterium tuberculosis, which also use the privileged environment of a
macrophage to survive intracellularly for extended periods of time (Pieters & Gatfield,
2002). Non-lytic expulsion of the new yeast cells means that less inflammation occurs,
reducing the local immune response, and enabling the infection to progress.
Many genes in C. neoformans exhibit large increases in expression when engulfed
by a macrophage. These genes encode proteins necessary for DNA repair, free radical
elimination, and anti-nitrosative processes, although the yeast is less able to deal with
nitrogen radicals than reactive oxygen species (Alspaugh & Granger, 1991). The cell wall
of C. neoformans contains molecules which trigger the M2 activation of macrophages,
which are less effective against the yeast than M1-activated macrophages (Martinez,
Helming, & Gordon, 2009). This unequal effectiveness of response is one mechanism by
which C. neoformans increases its rate of survival in macrophages. M1 macrophage
activation requires release of inflammatory cytokines, which the intracellular
reproduction method of C. neoformans reduces. M1 activated macrophages can
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successfully phagocytose and digest C. neoformans cells due to the reactive nitrogen
species produced by M1 activation (Alspaugh & Granger, 1991).
In case of a successful M1 macrophage activation, granulomas will be formed
around the Cryptococcus cells in the lung parenchyma and degrading enzymes are
released (Majka, Kasimos, Izzo, & Izzo, 2002). This reaction is heavily dependent on the
immunocompetency and genetics of the host, and is similar to the body’s response to
infection with tuberculosis (Qualls & Murray, 2016). If macrophages are depleted, then
not enough will be recruited to encapsulate the Cryptococcus infection and it will persist
(Huffnagle, Yates, & Lipscomb, 1991). Natural killer cells can also bind directly to the C.
neoformans cells and eliminate them by use of perforin (Levitz, Dupont, & Smail, 1994;
L. L. Ma et al., 2004). T-helper cells exhibit a fungistatic effect against C. neoformans
cells (Levitz et al., 1994). The lungs of AIDS patients are lacking in T-cells and
macrophages, and therefore afford little protection against cryptococcal sepsis (Shibuya
et al., 2005).
After invasion of the lungs and bloodstream, C. neoformans must cross the bloodbrain barrier (BBB). The exact mechanisms used by C. neoformans to cross this barrier
are still being investigated, but the yeast must pass through the endothelial lining of the
capillaries, the tight junctions surrounding those capillaries, and the astrocytes that
protect the neural tissue (Tseng et al., 2015). Monocytes have been shown to be a
necessary for successful crossing of the BBB by C. neoformans cells, indicating a trojan
horse effect (Charlier et al., 2009). Other modes of crossing have also been observed,
however, including a transcellular mechanism that does not require monocytes (Y. C.
Chang et al., 2004).
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Once the BBB has been crossed, the yeast is free to proliferate in the harsh but
isolated environment of the cerebrospinal fluid (CSF), as well as brain tissue. This ability
to thrive in the CSF is not common to all infectious yeasts (Lee et al., 2010). Multiple
abscesses are formed at the meninges and throughout the brain parenchyma, causing
fever and headache (Bicanic & Harrison, 2004; Y. C. Chang et al., 2004). Intracranial
pressure is also frequently increased during cryptococcosis, presumably due to physical
blockage of the arachnoid villi with yeast cells (Bicanic & Harrison, 2004). The
mechanism by which C. neoformans is able to survive in the CSF is currently unknown,
although several mutations that affect survival in the CSF have been identified (Lee et al.,
2010).
C. neoformans’ response to resistance by the host immune system is complex.
Sialic acid is incorporated into the cell wall and released from the cell. This chemical has
been shown to have a protective effect against phagocytosis by macrophages in the host
(Rodrigues et al., 1997). Sialic acid also helps to repel other cells by making the cell wall
of C. neoformans more negative. However, the capsule of C. neoformans is the most
effective defense against the host immune system. The capsule is a polysaccharide with a
mannose backbone. Glucuronic acid and xylose are both incorporated into the matrix of
the capsule as well (Doering, 2009).
The extracellular polysaccharide matrix has several unique functions. When IgG
antibodies bind to the C. neoformans cell, they frequently disappear beneath the surface
of the capsule, preventing them from aiding the macrophages in detection and
phagocytosis. Free fragments of the GXM capsule (glucuronic acid, xylose, and
mannose) have been shown to severely inhibit the effectiveness of the host immune
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response by essentially appearing as false positives all over the body, inhibiting the
response to actual sites of infection. Coat proteins on the capsule also reduce the host
response to the infection by reducing the number of co-stimulatory molecules produced
(Martinez et al., 2009).
The carbon cycle in C. neoformans is heavily focused on the use of glucose, much
like other eukaryotes. The Warburg effect suggests that C. neoformans tends to use
glycolysis, followed by lactic acid fermentation, to produce energy; this means that
demand for glucose will be extremely high for C. neoformans to successfully invade and
proliferate in a host (Vander Heiden, Cantley, & Thompson, 2009). This process is not
ordinarily energetically favorable, as the electron transport system can generate far more
ATP per glucose than aerobic glycolysis does. However, proliferating cells also need a
large variety of organic molecules that are energetically expensive to make from smaller
carbon molecules. By halting catabolism after production of pyruvate, the cell can
directly use the carbon from fermentation products at a lower energetic cost than would
be incurred by using the ATP produced by the citric acid cycle to construct entirely new
molecules, such as amino acids and NADPH (Vander Heiden et al., 2009). When this
central carbon utilization pathway is disrupted, severe attenuation of virulence results.
Numerous methods are being investigated to reduce the required length of
treatment to a manageable level for those without easy access to the required drugs for
extended treatment periods. This research is made more necessary by the difficulty in
obtaining flucytosine. This shortfall increases the need for alternative modes of treatment
for Cryptococcosis that can be delivered to areas where conventional medical care may
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be more difficult to obtain. A better understanding of the carbon usage of C. neoformans
could lead to new ways to inhibit its growth and aid recovery.
Regulation of C. neoformans virulence
Much of the genome of any species of any organism is made up of proteins that
solely affect the transcription of other genes. C. neoformans has many transcription
factors which are necessary for virulence, or at least for full virulence. These intracellular
targets are somewhat more difficult to access than a membrane-bound protein, but their
effects are widespread and profound.
GAT201 is a key regulator of virulence which has been shown to impart resistance
to macrophage function against C. neoformans based on factors other than capsule size.
This gene regulates over 1000 other genes, or roughly one sixth of the genome of C.
neoformans. GAT201 has also been shown to be active under conditions in which
macrophages would be present (Chun, Brown, & Madhani, 2011).
Overexpression of GAT201 has been shown to dramatically increase virulence in
the murine inhalation model (Liu et al., 2008). Overexpression mutants show increased
melanin production, especially on L-DOPA media, and can induce capsule formation
under conditions not normally associated with encapsulation (Liu et al., 2008).
Conversely, gat201∆ strains have shown drastically increased rates of phagocytosis by
bone macrophages, with approximately a five-fold increase in association between
macrophages and C. neoformans cells, as compared to strains with gross capsule defects
(Liu et al., 2008).
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The majority of the effect on virulence of GAT201 seems to be caused by its
regulatory effects on two other genes: GAT204, a transcriptional regulator, and BLP1,
which encodes a signal peptide (Chun et al., 2011). gat204Δblp1Δ double-knockouts
show very high levels of macrophage association when co-cultured, approaching a
significant percentage of that of the gat201∆ strain (Chun et al., 2011). However,
knockouts of these two regulated genes show no effect on capsule size, indicating the
source of protection from macrophages is mediated by other factors.
Blp1 was identified as a signal peptide which controls functions that have not yet
been elucidated; although, the presence of a Barwin-like domain indicates that it could
bind to polysaccharides (Svensson et al., 1992). There is some evidence that either
GAT204 is a repressor of BLP1, or that BLP1 transcription is increased when GAT204 is
not present, as in a gat204Δ knockout. blp1Δ strains show only slightly lower resistance
to phagocytosis compared to wild type C. neoformans. Its effect on virulence appears to
be largely synergistic with, and dependent on, the presence of a defective GAT204 gene.
Gat201 regulates two pathways in C. neoformans: the Gat204/Blp1 pathway and
an uncharacterized pathway that is not controlled by GAT204 or BLP1 (Chun et al.,
2011). This uncharacterized pathway also protects the cell from phagocytosis by alveolar
macrophages beyond the effect conferred by the Gat204/Blp1 pathway alone. C.
neoformans’ survival in the lung is severely impaired by the loss of GAT201, and its
infectivity is therefore greatly reduced as well. Further research is needed on the exact
functions of both Blp1 and Gat204 as it is currently unknown what the specific effects of
these two proteins are; although, the general functions have been inferred by homology
(Chun et al., 2011).
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SRE1 is a highly conserved gene among eukaryotes which regulates response to
low oxygen conditions (Hughes, Todd, & Espenshade, 2005). It was identified in C.
neoformans by homology to a similar gene in Schizosaccharomyces pombe. This gene
encodes a protein known as sterol regulatory element binding protein, which is believed
to be a membrane-bound transcription factor similar to mammalian SREBP (Bien, 2010).
The SRE1 gene appears to influence transcription of about 100 genes in C. neoformans
when under hypoxic (<1% O2) conditions (Yun C. Chang, Bien, Lee, Espenshade, &
Kwon-Chung, 2007).
As the mammalian brain is a relatively low oxygen environment, C. neoformans
must transition from its normal biosynthetic pathways to ones better suited to low oxygen
levels (Erecinska & Silver, 2001). SRE1 and SREBP are believed to be essential in
oxygen sensing in C. neoformans and are key regulators of virulence in both the
inhalation and tail vein injection murine models (Bien, 2010).
Ergosterol is a membrane associated lipid with properties similar to cholesterol
which is common among fungi and some protists. It is believed to serve a similar
function to cholesterol in membranes: regulating membrane fluidity. Because mammals
do not produce this lipid and it is localized at the cell membrane, ergosterol makes an
excellent target for antifungal drugs. Amphotericin B and the azole drugs target this
molecule. SRE1 is heavily involved in regulating synthesis of ergosterol at several key
points in the biosynthetic process (Yun C. Chang et al., 2007). Ergosterol synthesis
requires large amount of oxygen to synthesize, so its production is downregulated under
hypoxic or anoxic conditions in many organisms (Hughes et al., 2005). Unlike many
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other non-capsular virulence regulating genes, SRE1 has no detectable effect on survival
in alveolar macrophages (Yun C. Chang et al., 2007).
Iron and copper metabolism is also regulated by SRE1, with at least 6 different
iron or copper uptake proteins differentially upregulated under the effects of a functional
gene (Yun C. Chang et al., 2007). sre1∆ mutant strains showed greatly reduced growth
on limited iron medium, with the generational time increasing roughly four-fold (Yun C.
Chang et al., 2007). Restoration of the gene by complement at least partially restored
growth on low-iron media.
The transcription factor MIG1 is involved in regulation of the HAP complex,
transitioning the transcriptome of S. cerevisiae away from the use of alternative carbon
sources in the presence of glucose (Nehlin, Carlberg, & Ronne, 1991). A homologue of
MIG1 in C. neoformans shows similar traits, reducing the transcription of genes
necessary for galactose, raffinose, and maltose metabolism (Caza, Hu, Price, Perfect, &
Kronstad, 2016). Loss of MIG1 has a variety of effects, including repression of both
HAPX and CIG1, a putative heme-binding protein (Caza et al., 2016). The loss of CIG1
has been linked to a decrease in virulence (Cadieux et al., 2013). This decrease in
virulence is presumably caused by the loss of iron sourced from hemoglobin. MIG1 is
also linked with repression of genes necessary for the TCA cycle, including the genes
responsible for complexes I and III of the electron transport chain (Caza et al., 2016).
MIG1 is also required for resistance to reactive oxygen species, especially at 37*C (Caza
et al., 2016).
Deletion of MIG1 causes increased susceptibility to fluconazole, to tetracycline,
and to both anti-fungals combined (Caza et al., 2016). The mig1∆-induced sensitivity to
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the combination of fluconazole and tetracycline is especially pronounced. Deletion of
MIG1 has the opposite effect on sensitivity to caffeine and rapamycin. Survival on media
with these compounds was enhanced in mig1∆ mutants compared to wild type H99 C.
neoformans (Caza et al., 2016). Testing with high-salt media also showed reduced growth
for the mig1∆ strain compared to wild type.
Despite the sensitivities induced by deletion of MIG1, the mig1∆ mutant strain
did not show significantly reduced survival in murine macrophages (Caza et al., 2016).
However, deletion of HAPX in addition to MIG1 significantly reduced the rate of
survival in macrophages. Mig1∆ mutants were also able to establish an infection in the
murine inhalation model at a level similar to that of wild type H99 C. neoformans. The
mutant strain also showed much higher levels of tissue fungal burden in the blood, brain,
spleen, and liver at time of death compared to wild type. Deletion of HAPX in addition to
MIG1 significantly reduced infectivity, and reduced fungal burden in the previously
mentioned tissues to roughly the same level observed in mice infected with wild type
H99.
Mig1 seems to regulate sensitivity to a broad range of compounds. Deletion of
MIG1 causes an increase in sensitivity to fluconazole and tetracycline, but a decrease in
sensitivity to rapamycin. Rapamycin is not a viable candidate for anti-fungal treatment in
humans, as it is an immunosuppressant (Abraham & Wiederrecht, 1996). Those suffering
from a C. neoformans infection are already immunosuppressed, and rapamycin would
only cause further problems. The increased sensitivity to tetracycline and fluconazole
makes this gene an appealing target for further research on potential anti-fungals, as these
drugs are already widely used. Increasing their effectiveness could only be beneficial.
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Iron metabolism is a key pathway for invading pathogens. Extracellular iron
levels are normally maintained at a very low level in the human body to reduce its
availability to pathogens (Jung & Kronstad, 2008). CIR1 is an iron sensing protein in C.
neoformans which regulates many other genes related to iron metabolism (Jung, Sham,
White, & Kronstad, 2006). Interestingly, the effects exerted by CIR1 do not appear to be
dependent on regulation of its expression due to changing iron concentrations (Jung &
Kronstad, 2011b). Intracellular iron has been found to stabilize the Cir1 regulatory
protein, which can then bind to its target genes and reduce transcription. CIR1 has also
been linked to changes in mating and pheromone production, to capsule and melanin
production, to cell wall proteome, and to other metal ion homeostasis pathways (Jung &
Kronstad, 2011a, 2011b). Deletion of CIR1 also reduces ergosterol synthesis by reducing
expression of SRE1 (Jung et al., 2006).
Deletion of CIR1 reduces virulence drastically, with nearly all major virulence
markers missing (Jung et al., 2006). The cir1∆ mutant strain is more sensitive to
antibiotics and was unable to establish an infection in the murine inhalation model. CIR1
should make an excellent target for potential anti-fungals, as it appears to have homologs
in many other yeasts (Jung et al., 2006). Its effects on cellular metabolism and
homeostasis are extremely pronounced, and even small reductions in the efficacy of its
regulatory function could shorten treatment and improve clearance of a cryptococcal
infection.
SNF1 increases the ability of C. neoformans to grow on non-glucose media, by
activating numerous glucose repressed genes, and is a key regulator in reversing the
glucose effect when glucose levels are low. The presence of Snf1 is necessary for growth
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on galactose, sucrose, and maltose media in JEC21, although it is not essential for growth
of H99 on those media. This represents a divergence in carbon usage between the H99
and other yeasts (Celenza & Carlson, 1984, 1989). The function of wild-type SNF1 is to
reverse the repression of glucose-repressible enzymes and allow the cell to switch to a
secondary carbon source. This is achieved by increasing production of invertase, which
splits sucrose into glucose and fructose (Neumann & Lampen, 1967). Removal of this
gene by deletion made the JEC21 strain largely unable to grow on alternative carbon
sources.
Disruption of the gene SNF1, a key regulator of cryptococcal carbon usage,
results in defects in carbon usage, melanin production, and capsule formation (Yang et
al., 2010). Stress response regulation is also a function of this gene. C. neoformans strain
JEC21 snf1Δ mutants showed reduced growth on glycerol, galactose, and especially
sucrose media, indicating that the gene is responsible for the same functions in C.
neoformans as it is in S. cerevisiae. Reconstituted JEC21 showed restoration of normal
growth on those media. SNF1 has also been linked to regulation of growth at body
temperature. snf1Δ mutants are far less robust at 37°C compared to wild-type JEC21.
snf1∆ mutants from this strain also showed reduced ability to grow in media with high
cation concentration, as well as reduced overall virulence.
Given the wide variety of stress responses in which SNF1 is a vital component, it
is no surprise that snf1Δ mutants have reduced virulence. Mice injected with snf1Δ strains
of JEC21 survived for 72 days, on median, while those infected with the wild type strain
lasted only 20 (Yang et al., 2010). It is beyond the scope of this paper to infer whether the
defects in melanin and capsule production were the source of the reduced virulence, but
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the capsule is the major virulence factor of C. neoformans, so it is difficult to separate the
effects of metabolic defects from those caused solely by changes to the capsule.
snf1Δ strains show an unexplained temperature sensitivity at 45°C for two hours
or 35°C for two days. The presence of a functional SNF1 allele was necessary for
survival. Complemented and wild type JEC21 were both resistant to the heat treatment.
H99, again, was largely unaffected by the deletion of SNF1 for this test, further
emphasizing the divergent functions of SNF1 in the two strains. The role of SNF1 in heat
shock response is unclear, but it seems to have a regulatory effect on Hsf1, although it is
only one of several proteins that can participate in Hsf1 activation (Verghese, Abrams,
Wang, & Morano, 2012).
JEC21 also requires a functional SNF1 allele to survive stress induced by high
concentrations of cations. The snf1∆ strain of JEC21 was abnormally sensitive to high
concentrations of NaCl and hygromycin B. However, high sorbitol concentrations did not
elicit the same sensitivity, indicating that high osmolarity is not the source of the
sensitivity (Yang et al., 2010). snf1Δ H99 did not show increased sensitivity to the tested
ion concentrations. Nevertheless, the mutant H99 strain did show increased sensitivity to
amphotericin B, while the mutant JEC21 strain did not.
As mentioned previously, regulatory proteins make enticing targets for new antifungals due to their broad effects on numerous virulence factors of C. neoformans. Other
types of targets exist, however, and the digestive and transport enzymes of the cell also
have the potential to be effective targets for interference. The transport proteins in
particular are ideal because a potential drug targeted at the protein does not necessarily
have to make it through the cellular defenses and into the cytoplasm or nucleoplasm.
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However, metabolic enzymes tend to be much more central to the function of the
organism and are also worth investigating.
Pyruvate Kinase is a key enzyme in glycolysis, the central carbon utilization
pathway for most non-photosynthetic organisms. Successful acquisition of carbon is a
vital step in the infection process for pathogens, and C. neoformans is no exception.
Reduced ability to obtain biochemically useful carbon substrates can reduce ATP
production and impede production of other key molecules from the pentose phosphate
pathway. The CSF contains glucose that can be used by an invading pathogen that is able
to cross the blood brain barrier. Any reduction in the ability of C. neoformans to use this
glucose would reduce virulence and aid in clearing of the yeast from the host (Price et al.,
2011). Alternative pathways for carbon utilization exist, but an organism that cannot use
glucose is severely reduced in virulence.
Deletion of PYK1 from C. neoformans results in a strain that shows no defects in
capsule or melanin production, although it does display a temperature sensitivity at 37°C
(Price et al., 2011). However, this strain is prevented from growing on alternative media,
such as lactate or glycerol, by carbon catabolite repression. Even though the cell cannot
use the glucose, the presence of glucose still reduces the ability of the cell to obtain
carbon from other sources. Deletion of MIG1, the major carbon catabolite repressor
transcription factor, in the pyk1∆ background enables the strain to grow at near-wild type
levels on glycerol or lactate media, which do not require a functional pyruvate kinase
enzyme to enter oxidative phosphorylation. However, the mig1∆ pyk1∆ mutant also
displayed lower growth rates than those of wild type C. neoformans in permissive media.
The double-deletion strain also exhibits complete avirulence in the murine inhalation
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model, although the strain was extremely persistent in the lung with very little clearance
by macrophages observed (Price et al., 2011).
Additionally, production of ATP was drastically reduced in the pyk1∆ mutant,
which would explain its decreased survival relative to wild type C. neoformans in ex vivo
CSF(Price et al., 2011). The mig1∆ pyk1∆ double-mutant recovers ATP production in
CSF, although production is still below that of wild type. Presumably, the limited pool of
lactate accessible in the CSF results in lower ATP production after glucose repression is
removed (Price et al., 2011).
Drugs targeting the glycolytic pathway have not been used to treat fungal
infectious diseases yet, but the work by Price and colleagues suggests that an
appropriately targeted compound could exert a fungistatic effect on C. neoformans even
after it has crossed the blood-brain barrier and begun to colonize the meninges.
Presumably, a drug that targets Pyk1 would not also target Mig1 and intracellular ATP
levels could be drastically reduced, allowing more time for treatment by traditional
means or for clearance by the immune system.
Sterylglucosides are glycolipids which are produced by C. neoformans and are
present on its surface, but are digested by another enzyme to prevent their accumulation
(Watanabe et al., 2015). When this enzyme, known as EGCrP2, has been deleted from
the genome, these sterylglucosides have been shown to accumulate on the exterior of the
cell and trigger an appropriate immune response by the host. EGCrP2, which is an
endoglycoceramidase that destroys sterylglucosides on the exterior of the cell, is
necessary for full virulence of C. neoformans, and is encoded by the SGL1 gene (Rella et
al., 2015). Deletion of SGL1 does not affect other known virulence factors such as
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melanin production or capsule size, indicating that a novel protective effect is exerted by
expression of this gene.
Triggering of the TH2 immune response (described below) has been linked with
decreased effectiveness of immune response and increased overall susceptibility to
cryptococcosis. Infection with a sgl1∆ strain created by knockout from H99 C.
neoformans via the murine inhalation model resulted in null virulence (Rella et al., 2015).
Infection with the sgl1∆t strain also conferred complete immunity against further
infection by both the sgl1∆ strain and the wild-type H99 strain. This vaccine effect also
did not appear to be mediated by CD4+ T-cells, as mice depleted of CD4+ cells prior to
infection also survived infection with the sgl1∆ strain and received the immunity from
future infections previously observed. This is an exciting discovery, indicating that it is
very possible to create a vaccine against C. neoformans which could potentially be
effective even in patients with HIV/AIDS. While introduction of an attenuated strain of a
pathogen always carries the risk of a reversion mutation, this strain provides a potential
method to significantly reduce susceptibility to cryptococcosis.
A key component of phagocytic attack by macrophages is the use of oxygen
radicals to damage engulfed cells. Many organisms use the enzyme superoxide dismutase
to metabolize these peroxides and split them into less reactive components. Wild-type C.
neoformans has a functional superoxide dismutase gene; other enzymes with a similar
function further increase the ability of the yeast to deal with radicals (Cox et al., 2003).
TSA1 is a gene that has been identified by homology to an S. cerevisiae gene as a
2-cys peroxiredoxin, meaning that is has both an n-terminal and c-terminal cysteine that
form crosslinks (Missall, Pusateri, & Lodge, 2004). This enzyme confers additional
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protection against free radicals and significantly enhances C. neoformans’ ability to
survive phagocytosis. Under conditions of free radical stress, TSA1 production is
increased nearly four-fold in wild type C. neoformans (H99), indicating that this gene
used to fulfill its homology-hypothesized function (Missall et al., 2004). Production of
TSA1 is also upregulated at higher temperatures. This effect has been hypothesized to be
a result of changes in metabolism at 37°C which increase the amount of internally
produced oxygen radicals (Missall et al., 2004). Regardless of its control mechanisms,
TSA1 has been shown to be a vital part of the process of clearing free radicals.
Knockout mutants of TSA1 show drastically reduced survival in media containing
small amounts of hydrogen peroxide and t-butylhydroperoxide at 30°C (Missall et al.,
2004). Reconstitution of the gene resulted in a return to wild-type phenotype when grown
under oxidative conditions and virulence approaching that of H99 C. neoformans. This
data is consistent with the hypothesis that secondary peroxidases are a necessary
component for survival post-engulfment. Virulence in the murine inhalation model was
essentially zero for `infection to occur by the normal method. Injection of tsa1Δ C.
neoformans into the tail resulted in significantly increased virulence, although less than
that of H99 wild-type in an inhalation-infection model.
Echinocandins are a more recent class of anti-fungal than those traditionally used
to treat cryptococcosis: fluconazole and amphotericin B (Denning, 2003). This new class
of drugs is effective against many forms of fungi, including Aspergillus and Candida
species. However, these drugs are not effective at clinical doses against Cryptococcus
infections. The mechanism for this resistance was recently determined to be a lipid
flippase that is homologous with S. cerevisiae gene CDC50 (Huang et al., 2016).The
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gene responsible for resistance to the echinocandin anti-fungal drug caspofungin was
determined by growing a mutagenesis library of KN99 C. neoformans mutants on media
inoculated with the antibiotic (Huang et al., 2016).
Several mutants showed decreased growth under the above conditions, but the
cdc50Δ strain showed the greatest decrease in growth from the effects of caspofungin
alone. The flippase encoded by CDC50 could prove to be a potential target for new
drugs, as it is a protein not found in humans. The combination of a drug targeted at this
protein and an echinocandin antifungal could allow for a much shorter and less toxic
course of treatment than the current standard of care.
Zinc is also necessary for many functions within the cell. It is a component of
alkaline phosphatase, zinc-finger domains of many proteins including Mig1, and other
enzymes (Lulloff, Hahn, & Sohnle, 2004). The regulatory and uptake systems for zinc in
S. cerevisiae has been well characterized, but only recently have the plasma membrane
zinc transporters for C. neoformans been identified (Do, Hu, Caza, Kronstad, & Jung,
2016). The ZIP family of zinc transporters are the main family of proteins responsible for
maintaining intracellular zinc levels. The Zip1 transporter has been linked with zinc
uptake under low-zinc conditions, and Zip2 with intake under normal or zinc-replete
conditions. Zip1 is an N-glycosylated protein localized to the plasma membrane with 8
transmembrane domains. Zip2 is also a membrane-localized zinc transporter, but its
effect on virulence is negligible.
Deletion of ZIP1 resulted in decreased growth on low-zinc media, while deletion
of ZIP2 had little effect at any concentration of zinc (Do et al., 2016). Significantly
higher zinc levels were required for optimal growth for the zip1∆ mutant compared to the
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zip2∆ mutant, indicating that ZIP1 is responsible for high-affinity zinc transport. Deletion
of ZIP1 significantly reduced survival in macrophages, as well as virulence in the murine
inhalation model. Deletion of ZIP2 alone had little effect on either of these two tests,
further illustrating the dependence of C. neoformans on Zip1 for obtaining zinc. Deletion
of both ZIP1 and ZIP2 showed effects on virulence and macrophage survival similar to
those of the zip1∆ strain. The zip1∆ mutant strain also showed no change in melanin or
capsule formation compared to H99 wild type C. neoformans. The reduction in virulence
is therefore linked to the decreased ability of the cell to obtain zinc, rather than on other
mediating factors. Although deletion of ZIP1 does not cause a complete attenuation of
virulence, the relative ease of access to a membrane protein compared to an intracellular
target makes Zip1 an appealing target for new drugs. More research needs to be done to
determine whether deletion of ZIP1 causes increased susceptibility to other antifungals or
compounds.
Another active area of C. neoformans research is on the formation of titan cells,
which are large, polyploid cells (Okagaki & Nielsen, 2012). These titan cells can reach
100 microns in diameter, much larger than the normal vegetative C. neoformans cells that
are ≤ 10 microns in diameter. There are also numerous changes in the capsule of the cell
when a titan cell is formed, including increased cross-linking and decreased permeability.
Internal transformation also occurs in these cells, including increased amounts of DNA
and increased formation of vacuoles. As mentioned previously, these cells are polyploid.
Vegetative C. neoformans cells are haploid, but titan cells can be tetraploid, octoploid,
and may even be hexadecaploid (i.e. having 16 copies of the genome in a nucleus).
However, progeny of these titan cells are still haploid. The mechanism by which
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polyploid cells are produced from haploid cells is believed to be mitotic, but it is
currently unknown how polyploid titan cells are able to produce haploid progeny.
Movement of titan cells across membranes is also hampered by the large size of these
cells, meaning that it is unlikely they will ever leave the lung but may instead serve as a
source of dissemination.
Titan cell formation can be triggered by the presence of macrophages or other
phagocytic cells, such as amoebae. It has been postulated that sensing of phospholipids
commonly found in phagocytic cell plasma membranes is the trigger for titan cell
formation. Production of titan cells has been demonstrated to be controlled by multiple
intracellular pathways, including adenyl cyclase/cAMP control and G-protein coupled
receptors (Okagaki et al., 2011; Zaragoza et al., 2010). Titan cells are too large to be
engulfed, and therefore provide a relatively untouchable source of C. neoformans cells in
the alveolar tissue (Crabtree et al., 2012). Similar to the immune response to other
parasites, eosinophils are recruited to the lung, potentially indicating an alternative
activation of the immune system that is less effective at dealing with the non-titan
vegetative C. neoformans cells (Crabtree et al., 2012). The progeny of titan cells are more
resistant to oxidative and nitrosative stress than standard C. neoformans cells (Okagaki et
al., 2010). The method by which this protection from free radicals is conferred by the
titan cell is currently unknown.
Several genes have been identified as regulators of titan cell formation. Gpr5 is a
membrane protein that has been shown to be necessary for titan cell formation, and may
be a sensor that triggers the transition (Crabtree et al., 2012). It is unknown whether this
is the sensor that regulates response to coat lipids of macrophages. Ste3a is also believed
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to be a regulator for the titan cell formation process and is believed to be involved with
mating type a pheromone response (Okagaki et al., 2010). Both of these regulatory
proteins are believed to interact with Gpa1, which is another intermediate in the
regulatory pathway (Choi, Vogl, & Kronstad, 2012). RIM101 is also involved with
control of titan cells, and is necessary for titan cell formation (O'Meara et al., 2010).
Deletion of these genes and the resulting decrease in titan cell formation showed
significantly lowered virulence in the murine inhalation model (Crabtree et al., 2012).
It is believed that the effects on virulence of the titan cells that are not mediated
by the changes to the capsule are due to alternative activation of the immune system
(Crabtree et al., 2012). Similar to how C. neoformans cells cause M2 activation of
macrophages, activation of the TH2-type immune response is maladaptive. Alterative
activation of the immune system to deal with the large titan cells tends to reduce response
to the normally-sized vegetative cells, allowing them to proliferate while eosinophils
attack the titan cells. Titan cells are extremely resistant to this type of attack, however,
and can remain in the lung for months (Crabtree et al., 2012). Mice which showed TH2
type immune activation had much higher rates of dissemination across the blood-brain
barrier, and also showed reduced recruitment of T and B-cells to the lungs (GarciaBarbazan et al., 2016).
Conclusion
As would be expected from any complex organism, the list of genes that are
necessary for full virulence is long and varied. Many of the genes discussed in this paper
would make good candidates for new drugs, and could substantially increase survival if
their target genes or proteins could be inhibited. Resistance to antibiotics is always a
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concern with any long-lasting infection, and the current treatment plans for a C.
neoformans infection very extended in length and form a fertile breeding ground for
resistant phenotypes. Fortunately, the fungal genome is relatively resistant to change, and
complete resistance to the azole drugs is very rare.
Other methods could also be used to control the spread of C. neoformans. Pigeons
have been documented as carriers of this disease, and their droppings are believed to be
the most common way the illness spreads. Population control of wild pigeons could
therefore be used to limit spreading of the disease. Similarly, in Australia, a type of
Eucalyptus tree has been shown to be a reservoir of C. gattii in the wild. Finding ways to
remove or disinfect the trees could be a potential way to reduce to effects of
cryptococcosis on the population.
Ultimately, however, as long as AIDS is present in the world, cryptococcal
infections will occur. The organism is ubiquitous, and extremely hardy and long lasting.
Programs designed to preserve innate immunity will be more effective in the long run
than trying to replace the functionality of an immune system with more drugs.
Knowledge obtained about the regulatory pathways and cellular defenses of C.
neoformans against the immune system can also be used to create treatments for C. gattii,
which does not require that the host lack a functional immune system. This emerging
disease could cause massive damage if it became resistant to current antifungals, as the
infection is very difficult to treat, and is usually not detected until the patient experiences
symptoms related to encephalitis or meningitis.
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The Zip1 transporter should be a relatively safe target for new antifungals. The
CSF is a relatively isolated environment, so any drugs introduced to that reservoir have
many fewer potential human cells that could be negatively impacted. Care must be taken
to ensure that neural tissue is not harmed by the introduction of drugs to the CSF, but
presumably at least one of the proteins discussed above will be completely unique to
fungi and cause few side effects.
For the borderline immunocompetent, finding ways to stimulate M1 activation of
macrophages rather than the M2 activation encouraged by C. neoformans is probably the
best option. Stopping the infection in the alveolar tissue of the lung is obviously
preferable to treating the disease after infection of the CSF.
New antifungals are constantly in development, and it remains to be seen how
effective the latest class of azoles will be against C. neoformans. Isavuconazole,
developed for treatment of infection by Aspergillus species, targets the production of
ergosterol. Ergosterol, as mentioned above, has been shown to be necessary for virulence
in C. neoformans, so this drug has the potential to be useful in treating cryptococcosis.
However, another azole drug will most likely not be sufficient to significantly reduce the
burden of treatment for cryptococcosis. Some method of allowing the immune system to
appropriately respond to the yeast would be ideal, preferably by enabling CD8+
lymphocytes, which are not depleted by infection with HIV, to successfully phagocytize
and destroy the pathogen (Daniel et al., 2001). A drug that could potentially shut down a
key regulator such as Cir1 could reduce the metabolic capabilities of the cell and make it
unable to defend against the use of superoxide radicals inside of the macrophage.
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Like alternative M2 macrophage activation, triggering of TH2-type immune
response by C. neoformans titan cells decreases the effectiveness of macrophages and
increases dissemination across the blood-brain barrier. If proper stimulation of the
immune system can be achieved, treatment is far more likely to be successful and short.
As before, the ideal solution is to encourage the immune system to respond appropriately
rather than to necessitate extended use of antifungals to prevent reinfection.
C. neoformans and C. gattii are emerging pathogens that have seen a drastic
increase in infection as the frequency of AIDS infection has increased. While
cryptococcosis kills thousands every year, it is currently still treatable by standard
antifungal drugs with a high survival rate. However, difficulties in obtaining the
necessary antibiotics, as well as the length of treatment prevent members of isolated or
low-income areas from being able to complete a full course of treatment. Finding new
drugs that target the pathways discussed herein should be a priority for the medical
research community.
As with other common microbial infections, the development of strains that are
resistant to the current drugs of choice is a concern. If more antifungals can be created
that are effective against C. neoformans, the emergence of highly resistant strains can be
delayed by allowing rotation of antifungals and for antibiotics of last resort to remain
effective. Again, like other microbial infections, early detection is the key to preventing
loss of life from the disease. Regular screening of those with HIV/AIDS for C.
neoformans infection could help save lives without the introduction of new treatment
methods.
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The possibility of a viable vaccine is also being explored, and has the potential to
revolutionize the treatment of cryptococcosis in a way that reactive treatment can never
hope to match. Research on vaccination against C. neoformans is still at the very
beginning stages, but this approach holds considerable promise for those who may
become infected with C. neoformans in the future.
The recent outbreaks of C. gattii are also concerning, and highlight further the
need for better research on Cryptococcus, as well as more drugs that are effective against
this hardy pathogen. Several of the mutations described in this paper have the potential, if
targeted, to allow current and newly created antifungals to be more effective. Whether the
method of attack is to synergize with existing drugs or to create entirely new courses of
treatment, the result will be shortened treatment times and increased effectiveness of
treatment. These two accomplishments would make full and successful treatment a
possibility for many who are currently unable to afford or find appropriate treatment.
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